Evidence from Biomarkers and Surrogate Endpoints

NeuroRx

Volumn 1, Issue 3, 2004, Pages 323-330

  Feigin, Andrew ^a  

^a North Shore Long Island Jewish Research Institute ^*  (United States)

Author keywords

Biomarker; endpoint; evidence; surrogate; therapeutics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; NEUROANATOMY; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; METHODOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; REVIEW; STANDARD;

ANIMALS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN;

EID: 23844545908     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.3.323     Document Type: Article

References (72)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
2. De Milito A., Titanji K., and Zazzi M. Surrogate markers as a guide to evaluate response to antiretroviral therapy. Curr Med Chem 10 (2003) 349-365
3. Fleming T. Surrogate markers in AIDS and cancer trials. Stat Med 13 (1994) 1423-1435 [discussion 1437-1440]
4. Morrish P. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?. Mov Disord 18 Suppl 7 (2003) S63-S70
5. Claes S., Van Zand K., Legius E., Dom R., Malfroid M., Baro F., et al. Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 52 (1995) 749-753
6. MacMillan J., Davies P., and Harper P. Molecular diagnostic analysis for Huntington's disease: a prospective evaluation. J Neurol Neurosurg Psychiatry 58 (1995) 496-498
7. Wang V., Yeh T., Chen C., Yan S., and Soong B. Usefulness of molecular testing in Huntington's disease. Zhonghua Yi Xue Za Zhi 62 (1999) 586-590
8. Rubinsztein D., Barton D., and Ferguson-Smith M. Issues in Huntington's disease testing. Q J Med 87 (1994) 71-73
9. Sanchez A., Castellvi-Bel S., Mila M., Genis D., Calopa M., Jimenez D., et al. Huntington's disease: confirmation of diagnosis and presymptomatic testing in Spanish families by genetic analysis. J Neurol Neurosurg Psychiatry 61 (1996) 625-627
10. Pirttila T., and Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol Scand 92 (1995) 468-471
11. Michalowska-Wender G., Losy J., and Wender M. Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients. Folia Neuropathol 39 (2001) 1-5
12. Fortini A., Sanders E., Weinshenker B., and Katzmann J. Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index. Am J Clin Pathol 120 (2003) 672-675
13. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (2001) 2089-2094
14. Burn D., Sawle G., and Brooks D. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 57 (1994) 278-284
15. Arnold D., and Matthews P. MRI in the diagnosis and management of multiple sclerosis. Neurology 58 Suppl 4 (2002) S23-S31
16. Bylesjo I., Brekke O., Prytz J., Skjeflo T., and Salvesen R. Brain magnetic resonance imaging white-matter lesions and cerebrospinal fluid findings in patients with acute intermittent porphyria. Eur Neurol 51 (2004) 1-5
17. Debaene A., Lavieille J., Vion-Dury J., Stanoyevitch J., Saint-Jean J., and Legre J. Contribution of MRI to the diagnosis of multiple sclerosis. J Neuroradiol 13 (1986) 1-10
18. Corea F., Tambasco N., Luccioli R., Ciorba E., Parnetti L., and Gallai V. Brain CT-scan in acute stroke patients: silent infarcts and relation to outcome. Clin Exp Hypertens 24 (2002) 669-676
19. Corea F., Henon H., Pasquier F., and Leys D. Silent infarcts in stroke patients: patient characteristics and effect on 2-year outcome. J Neurol 248 (2001) 271-278
20. Bernick C., Kuller L., Dulberg C., Longstreth Jr. W., Manolio T., Beauchamp N., et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57 (2001) 1222-1229
21. Leary M., and Saver J. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis 16 (2003) 280-285
22. Simon J., and Thompson A. Is multiple sclerosis still a clinical diagnosis?. Neurology 61 (2003) 596-597
23. McDonald W., Compston A., Edan G., Goodkin D., Hartung H., Lublin F., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
24. Mitchell L. Radiology quiz. MRI in the diagnosis of multiple sclerosis. Aust Fam Physician 27 (1998) 631-632
25. Hampel H., Buerger K., Kohnken R., Teipel S., Zinkowski R., Moeller H., et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49 (2001) 545-546
26. Hampel H., Goernitz A., and Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull 61 (2003) 243-253
27. Morishima-Kawashima M., and Ihara Y. Alzheimer's disease: beta-amyloid protein and tau. J Neurosci Res 70 (2002) 392-401
28. Antonini A., Leenders K., Vontobel P., Maguire R., Missimer J., Psylla M., et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120 (1997) 2187-2195
29. Acton P., Mozley P., and Kung H. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease. Eur J Nucl Med 26 (1999) 1413-1423
30. Brooks D. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 43 Suppl 6 (1993) S6-S16
31. Tzen K., Lu C., Yen T., Wey S., and Ting G. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 42 (2001) 408-413
32. Eidelberg D., Moeller J., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45 (1995) 1995-2004
33. Feigin A., Antonini A., Fukuda M., De Notaris R., Benti R., Pezzoli G., et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 17 (2002) 1265-1270
34. Stacy M., and Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurol Clin 10 (1992) 341-359
35. Beal M. Huntington's disease, energy, and excitotoxicity. Neurobiol Aging 15 (1994) 275-276
36. Kieburtz K. Antiglutamate therapies in Huntington's disease. J Neural Transm 55 Suppl (1999) 97-102
37. Reynolds G., and Pearson S. Glutamate in Huntington's disease. Lancet 344 (1994) 189-190
38. Sanberg P., and Johnston G. Glutamate and Huntington's disease. Med J Aust 2 (1981) 460-465
39. A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 (2001) 397-404
40. Ellenberg S. Surrogate endpoints: the debate goes on. Pharmacoepidemiol Drug Saf 10 (2001) 493-496
41. Morrish P. The harsh realities facing the use of SPECT imaging in monitoring disease progression in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003) 1447
42. Whone A., Watts R., Stoessl A., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
43. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
44. Biglan K., and Holloway R. Surrogate endpoints in Parkinson's disease research. Curr Neurol Neurosci Rep 3 (2003) 314-320
45. Ansell B. Cholesterol, stroke risk, and stroke prevention. Curr Atheroscler Rep 2 (2000) 92-96
46. Bots M., Elwood P., Nikitin Y., Salonen J., Freire de Concalves A., Inzitari D., et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 56 Suppl 1 (2002) i19-i24
47. Bowman T., Sesso H., Ma J., Kurth T., Kase C., Stampfer M., et al. Cholesterol and the risk of ischemic stroke. Stroke 34 (2003) 2930-2934
48. Moroney J., Tang M., Berglund L., Small S., Merchant C., Bell K., et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282 (1999) 254-260
49. Sheikh K. High-density lipoprotein cholesterol and risk of stroke. JAMA 286 (2001) 1573-1574
50. Schuchert A., Behrens G., and Meinertz T. Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke. Pacing Clin Electrophysiol 22 (1999) 1082-1084
51. Yu D., Schaefer P., Rordorf G., and Gonzalez R. Magnetic resonance angiography in acute stroke. Semin Roentgenol 37 (2002) 212-218
52. Bunt T., and Cropper L. The role of complete cerebral angiography in the evaluation of patients with prior stroke. Am Surg 53 (1987) 77-79
53. Ballantyne C. Surrogate endpoints and newer risk markers in atherosclerosis management. Am J Manag Care 7 Suppl 5 (2001) S144-S147
54. Amoli S., and Turski P. The role of MR angiography in the evaluation of acute stroke. Neuroimaging Clin N Am 9 (1999) 423-438
55. Wu W., Huo S., Cheng C., Hong C., and Tsai S. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 44 (2001) 172-175
56. Yu Y., Chen T., Hong C., Chen H., and Tsai S. Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 28 (2003) 1182-1185
57. FDA approves clozapine for treatment of schizophrenia; careful monitoring required. Hosp Community Psychiatry 40 (1989) 1310
58. Olanow C. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 57 (2000) 263-267
59. De Gruttola V., Clax P., DeMets D., Downing G., Ellenberg S., Friedman L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials 22 (2001) 485-502
60. Bucher H., Guyatt G., Cook D., Holbrook A., and McAlister F. Users' guides to the medical literature. XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 282 (1999) 771-778
61. Zhang Y., Dawson V., and Dawson T. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7 (2000) 240-250
62. Youdim M., Grunblatt E., Levites-Royak Y., and Mandel S. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Adv Neurol 86 (2001) 115-124
63. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S26-S38
64. Jenner P., and Olanow C. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 Suppl 3 (1996) S161-S170
65. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., et al. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol Signals Recept 10 (2001) 224-253
66. Peck C., Rubin D., and Sheiner L. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther 73 (2003) 481-490
67. Food and Drug Administration Modernization Act of 1997. Public Law 105-115, Page 111, STAT 2295, 1997.
68. Prentice R. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989) 431-440
69. Echt D., Liebson P., Mitchell L., Peters R., Obias-Manno D., Barker A., et al. Mortal and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
70. Ravina B., Fagan S., Hart R., Hovinga C., Murphy D., Dawson T., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
71. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46 (1989) 1052-1060
72. Landau W. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 40 (1990) 1337-1339